Plain-English translation of NCT06887036 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a small pilot study testing whether can help treat chronic hepatitis B infection. The medication is being tested at increasing doses to see if it can reduce viral markers in your blood, potentially allowing you to stop long-term antiviral treatment. Currently available treatments work but require lifelong use; this study explores whether the new treatment might offer a better path forward.
Most hepatitis B patients must take antiviral medications for life, which is costly and can lead to drug resistance. Recent research suggests that if viral markers drop significantly, patients may be able to stop treatment entirely — but current medications rarely achieve this. This medication is being tested because early lab studies suggest it may be more effective at reducing these viral markers than existing options.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth as capsules for 6 months, starting at a low dose. Every 8 weeks, your doctor will check your blood work to see if the treatment is working; if not, your dose will be increased. After 6 months of treatment, you'll be followed for another 6 months with blood tests to see how long any benefit lasts. The entire study lasts one year total.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Switzerland